- Home
- EVGOW vs LYEL Comparison
EVGOW vs LYEL Comparison
Compare EVGOW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVGOW | LYEL |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | 376 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVGOW | LYEL |
|---|---|---|
| Price | $0.02 | $19.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 27.4K | ★ 81.1K |
| Earning Date | 03-07-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,306,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17,438.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 73.08 | N/A |
| 52 Week Low | $0.01 | $0.39 |
| 52 Week High | $0.38 | $45.00 |
Technical Indicators
Market Signals| Indicator | EVGOW | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 37.62 |
| Support Level | $0.01 | $16.20 |
| Resistance Level | $0.08 | $27.30 |
| Average True Range (ATR) | 0.00 | 2.07 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 12.07 | 21.45 |
Price Performance
Historical ComparisonAbout EVGOW EVgo Inc.
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.